adalimumab + denosumab + etanercept + rituximab

This is a combination of four distinct biologic disease-modifying antirheumatic drugs (DMARDs): adalimumab (TNF inhibitor), denosumab (RANKL inhibitor), etanercept (TNF inhibitor), and rituximab (anti-CD20 monoclonal antibody). While various combinations of these biologics have been studied in clinical settings, particularly for rheumatoid arthritis and other inflammatory conditions, there is no standard therapeutic regimen that includes all four medications simultaneously. Combinations of these biologics are generally approached with caution due to potential increased risk of infections and other adverse events.